In this article, we will be looking at the 11 best short-term stocks to invest in.

The latter half of the 2025 market is caught between conflicting signals. July’s controversial jobs report indicated the nonfarm payrolls rising by just 73,000, with three-month average job gains now less than a third of last year’s pace, pointing to a economic slowdown in the U.S. According to CNBC, this has prompted Goldman Sachs to reduce the growth forecast to just 1% for the remainder of 2025 citing weaker job growth and reduced consumer spending in the face of tariff-related inflation.

On the other hand, despite these warnings, the market remains resilient and continues to thrive. The Dow Jones Industrial Average declined by just 1.7% over the past month. And with President Trump’s announcement on the matter, optimism is brimming around possible Fed rate cuts and a breakthrough in U.S.-EU trade talks. Inflation concerns have been toned down, leading the traders to assign a nearly 90% probability of a rate cut in September. The improved sentiment has created short-term opportunities for investors to capitalize on.

Short-term opportunities often emerge in uncertain macro environments, and right now, the mix of market resilience and shifting Fed expectations is building such a setup. With that in mind, let’s look into our picks for the 11 best short-term stocks to consider. The top 5 might surprise you.

Our Methodology

When putting together our list of 11 best short-term stocks to invest in, we followed a few criteria. Primarily, we considered small caps and above for making this list. All the stocks on our list have a 1-year negative performance and a positive performance this week, which are used for recognizing their short-term return-generating potential. For ranking the stocks, we have used their 1-year negative performances. All the data used in the article was taken from financial databases and analyst reports, with all information updated as of August 7, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

11. Energizer Holdings, Inc. (NYSE:ENR)

Performance 1 Year: -2.32%

Energizer Holdings, Inc. (NYSE:ENR) ranks among our list of 11 best short-term stocks to invest in. The company sees mixed analysts’ opinions amid the company’s release of the Q3 earnings report for 2025.

Missouri-based company, Energizer Holdings, Inc. (NYSE:ENR), is among the world’s largest manufacturers of primary batteries and portable lights. With a comprehensive portfolio that includes brands like Energizer, Eveready, Rayovac, and Varta, the company markets automotive and personal care products to retailers, distributors, and direct consumers across various channels in over 165 countries.

In its 2025 third-quarter earnings report, released on August 4, 2025, the company announced that it exceeded its outlook across net sales, adjusted gross margin, and adjusted EPS. Particularly, the recent acquisition of Advanced Power Solutions NV (APS NV) contributed $20.8 million to Net Sales. In addition to this, Energizer Holdings, Inc. (NYSE:ENR)’s “Project Momentum” delivered approximately $12 million in savings during the quarter, indicating successful internal operational efficiency initiatives.

Acknowledging the growth, analysts, including Truist and UBS, raised their price target on the stock. Truist raised the price target from $30 to $35 while UBS raised it from $23 to $29. On the other hand, Canaccord Genuity maintains a Hold rating on Energizer Holdings, Inc. (NYSE:ENR), signaling mixed opinions on the stock.

The company gained 27.23% this week, sharply reversing its modest annual decline of 2.32%, increasing its appeal to investors seeking short-term investments in the consumer staples sector.

10. Teradyne, Inc. (NASDAQ:TER)

Performance 1 Year: -12.17%

Teradyne, Inc. (NASDAQ:TER) earns a rank in our list of 11 best short-term stocks to invest in. The company experienced an upward movement in stock price following better performance in the Semiconductor Test segment and the launch of Magnum 7H.

Headquartered in Massachusetts, Teradyne, Inc. (NASDAQ:TER) designs, manufactures, and sells automated test equipment for semiconductors and electronics. The company also focuses on robotics solutions, including collaborative and mobile robots through subsidiaries like Universal Robots and Mobile Industrial Robots.

On July 29, 2025, Teradyne, Inc. (NASDAQ:TER) reported its second-quarter 2025 results, with revenue of $652 million surpassing the company’s mid-point guidance ranges. The Semiconductor Test segment, which generated $492 million in revenue due to System-on-a-Chip (SOC) applications for artificial intelligence (AI), was the primary contributor. The company’s CEO, Greg Smith, has made the following statement:

“The exact timing of program ramps and capacity adds remain uncertain, but we believe that AI will drive strong second half performance for Teradyne.”

Furthermore, on August 4, 2025, Teradyne launched the Magnum 7H, a next-generation memory tester specifically designed for High Bandwidth Memory (HBM) devices integrated with GPUs and accelerators in high-performance, generative AI servers. Currently, in the production and shipping process of the Magnum 7H system to HBM manufacturers, the company claims that its new launch solidifies its market leadership by supporting current and future HBM technologies.

Teradyne, Inc. (NASDAQ:TER)’s stock price jumped 18.09% this week, hinting at strong near-term sentiment despite a 12.17% drop over the past year.

9. Ameresco, Inc. (NYSE:AMRC)

Performance 1 Year: -14.35%

Ameresco, Inc. (NYSE:AMRC) earns a rank in our list of 11 best short-term stocks to invest in. A flurry of significant project announcements and completions brings a significant positive change to the company’s stock price.

Founded in Massachusetts, Ameresco, Inc. (NYSE:AMRC) is a leading energy solutions provider in the U.S. The company offers infrastructure upgrades, smart energy systems, and renewable generation projects across the U.S., Canada, and Europe. It works with a wide range of clients, such as governments, utilities, and commercial businesses, to implement energy solutions tailored to their specific needs.

On July 9, 2025, the company announced a landmark $240 million hydropower project in Alaska. With this significant project, the company projected its capabilities in major infrastructure development.

And on July 23, 2025, Ameresco, Inc. (NYSE:AMRC) declared the completion of comprehensive energy modernization improvements at Southeast New Mexico College (SENMC). The project is expected to save the college over $141,000 annually under a 20-year operations and maintenance (O&M) contract. On the same day, the company also reported the expansion of its long-standing partnership with the University of Illinois Chicago (UIC) through a new $30 million Phase 2 Energy Efficiency Project.

With these developments, the company saw its stock price surge by 39.15% this week, marking a strong short-term comeback from a 14.35% annual decline and raising its appeal to investors seeking short-term investments.

8. PG&E Corporation (NYSE:PCG)

Performance 1 Year: -17.73%

PG&E Corporation (NYSE:PCG) secures a position in our list of 11 best short-term stocks to invest in. The booming data center demand and strong Q2 results are redefining the company’s position in the market.

California-based company, PG&E Corporation (NYSE:PCG) is the parent entity of Pacific Gas and Electric Company, an investor-owned utility delivering electricity and natural gas to approximately 5.5 million electric and 4.5 million gas customers across northern and central California. The company covers a service area of close to 70,000 square miles.

On July 31, 2025, PG&E Corporation (NYSE:PCG) announced that its data center demand pipeline had expanded to an impressive 10 gigawatts (GW) over the next ten years, positioning the company as a critical enabler for the burgeoning artificial intelligence (AI) and digital transformation sectors, which require immense power consumption.

PG&E Corporation (NYSE:PCG) also reported solid second-quarter 2025 financial results on July 31, 2025. In the report, the company has reaffirmed its non-GAAP core EPS guidance for the full year 2025 in the range of $1.48 to $1.52 per share. In addition, it has highlighted its achievements during the quarter, which included connecting over 3,300 new electric customers and 2,000 new electric vehicle charging ports.

Renewed interest in stock is evident as PG&E Corporation (NYSE:PCG) gained 8.43% this week despite a 17.73% annual decline, suggesting the high short-term return capabilities of the company.

7. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Performance 1 Year: -26.80%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) secures a spot in our list of 11 best short-term stocks to invest in. A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks’ performance.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company’s lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies.

On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company’s common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ closing share price on August 4, 2025, the last full trading day before the transaction announcement.

The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’ lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments.

6. FTAI Infrastructure Inc. (NASDAQ:FIP)

Performance 1 Year: -28.41%

FTAI Infrastructure Inc. (NASDAQ:FIP) merits inclusion in our list of 11 best short-term stocks to invest in. Weekly performance sees an uptick following the announcement of the Q2 earnings release date and the acquisition of The Wheeling Corporation.

FTAI Infrastructure Inc. (NASDAQ:FIP) invests in North American infrastructure assets across freight rail, ports and terminals, and power and gas. Following its 2022 spin-off from FTAI Aviation, the New York City-based company manages high-barrier-to-entry infrastructure that has been developed to deliver stable cash flows and growth.

On July 9, 2025, the company announced that it will be releasing its Q2 earnings results on August 7, 2025. Following this announcement, its recent weekly performance saw an elevation of up to 14.70%, signaling the positive expectations regarding the second quarter results.

Additionally, on August 6, 2025, FTAI Infrastructure Inc. (NASDAQ:FIP) announced entering an agreement to acquire The Wheeling Corporation for $1.05 billion. The Wheeling Corporation owns the Wheeling & Lake Erie Railway Company, and through its acquisition, FTAI Infrastructure Inc. (NASDAQ:FIP) could potentially optimize its freight rail platform by combining Wheeling with its existing Transtar operations.

Following this announcement and having reversed part of its 28.41% annual loss through its weekly performance uptick, FTAI Infrastructure Inc. (NASDAQ:FIP) stands attractive to short-term momentum traders seeking infrastructure recovery.

5. STAAR Surgical Company (NASDAQ:STAA)

Performance 1 Year: -32.37%

STAAR Surgical Company (NASDAQ:STAA) holds a place on our list of 11 best short-term stocks to invest in. Significant price movements were noted this week following the announcement of a takeover agreement from Alcon.

California-based company, STAAR Surgical Company (NASDAQ:STAA) develops, manufactures, and markets implantable, foldable Collamer® lenses and delivery systems for cataract and refractive eye surgery. The company has sold over 3 million lenses globally and consistently serves patients requiring visual clarity with minimally invasive procedures. Business operations span more than 75 countries.

On August 5, 2025, Alcon, a global leader in eye care, agreed to acquire STAAR Surgical. The terms of the agreement state that Alcon will purchase all outstanding shares of STAAR common stock for $28 per share. The offer represents an approximate 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) and a substantial 51% premium to the closing price of STAAR common stock as of August 4, 2025. The total equity value of the transaction is approximately $1.5 billion, and it is expected to be carried out in cash.

The acquisition primarily includes STAAR Surgical Company (NASDAQ:STAA)’s EVO family of ICL lenses. Alcon aims to integrate it to provide a leading surgical vision correction solution for individuals with moderate to high myopia.

STAAR Surgical Company (NASDAQ:STAA)’s stock price spiked 45.43% this week and signals a powerful but limited-time opportunity for short-term investors, despite a 32.37% annual decline.

4. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Performance 1 Year: -32.78%

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) finds its way to our list of 11 best short-term stocks to invest in. The company’s weekly stock price performance surges following FDA approvals for EMPAVELI, second-quarter 2025 financial results, and capped royalty purchase agreements.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), headquartered in Massachusetts, is a global biopharmaceutical enterprise advancing treatments for diseases through complement system modulation. The company has pioneered first-in-class C3-targeting therapies for conditions such as geographic atrophy, rare kidney disorders, and PNH.

On July 28, 2025, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) received U.S. FDA approval for EMPAVELI for the treatment of patients 12 years and older with C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN). With this approval, EMPAVELI becomes the first and only FDA-approved treatment for primary IC-MPGN, adolescent patients with C3G, and post-transplant C3G disease recurrence, thus capturing the unmet demands for the drug.

On July 31, 2025, the company reported its Q2 2025 financial results, showing $178.5 million in total revenues. SYFOVRE U.S. net product revenue reached $150.6 million, with demand growing 6% quarter-over-quarter, maintaining its market leadership in GA.

In the report, the company also highlighted a capped royalty purchase agreement with Sobi, under which it would receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli, including an upfront cash payment of $275 million. With this, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) focuses on pipeline development and commercial expansion without immediate financial pressure.

Following these developments, the stock price went up 27.70% this week, making a turnaround from its 32.78% yearly loss and drawing interest from traders eyeing biotech bounce-backs.

3. Tidewater Inc. (NYSE:TDW)

Performance 1 Year: -33.14%

Tidewater Inc. (NYSE:TDW) made the cut for our list of 11 best short-term stocks to invest in. With slim but definite positive results in the second quarter and the successful completion of a refinancing transaction, the company pushes its value up in the market.

Based in Texas, Tidewater Inc. (NYSE:TDW) is the industry-leading provider of offshore support vessels (OSVs).  Founded in 1956, the company offers marine support services to the offshore energy industry, including transportation of crews and supplies, towing and anchoring mobile rigs, and assisting with offshore construction projects.

On August 4, 2025, Tidewater Inc. (NYSE:TDW) reported strong second-quarter 2025 results. The revenue during the period reached $341.4 million, a 0.6% increase compared to the same period in 2024. In the report, the company also highlighted achieving a record average day rate of $23,166 per day, marking a 9.6% improvement year-over-year and a sequential increase of over $860 per day.

Following the second quarter, in July 2025, the company successfully carried out a refinancing transaction, completing a $650.0 million senior unsecured notes offering, which was primarily used to redeem previously outstanding Nordic bonds and a term loan facility. Additionally, with the establishment of a new $250.0 million revolving credit facility, Tidewater Inc. (NYSE:TDW) strengthens the company and ensures greater financial flexibility.

The company incurred a 33.14% annual decline but managed to rally its stock price by 20.22% this week, showing off its short-term return-generating capabilities to shareholders.

2. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Performance 1 Year: -42.86%

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) earns a spot on our list of 11 best short-term stocks to invest in. Amid revenue surges from the existing drugs, Revuforj and Niktimvo in Q2, FDA grants Priority Review for Revuforj’s sNDA.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a commercial-stage oncology company developing innovative cancer therapies through novel combinations and targeted agents in hematological and solid tumors. Operating from its headquarters in Massachusetts, the company has two FDA-approved products, Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab), a monoclonal antibody that blocks the CSF-1 receptor.

The company reported its Q2 financial results on August 4, 2025, where it highlighted $28.6 million in Revuforj net revenue, a 43% growth compared to the first quarter of 2025. Additionally, Niktimvo, in its first full quarter of launch, generated $36.2 million in net revenue, with Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s collaboration revenue from it amounting to $9.4 million, and the product already proving profitable for the company.

Additionally, the FDA has granted a Priority Review for Revuforj’s supplemental New Drug Application (sNDA) in relapsed or refractory mutant NPM1 (mNPM1) acute myeloid leukemia, with a PDUFA action date of October 25, 2025. The Priority Review potentially increases the likelihood of approval and improves the company’s outlook among investors.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s stock soared 21.45% this week, offering a notable short-term upswing despite a 42.86% annual decline.

1. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Performance 1 Year: -67.38%

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) holds a spot among our list of 11 best short-term stocks to invest in. The company sees its Buy rating reiterated following promising results from its clinical trials, including the VERITAC-2 trial.

Headquartered in California, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for women’s cancers. Its lead product candidate, palazestrant (OP-1250), is an estrogen receptor (ER) antagonist and degrader being evaluated in clinical trials for breast cancer. The company also has another drug candidate, OP-3136, a KAT6 inhibitor, in Phase 1 clinical trials.

In its Q1 earnings report, released on May 13, 2025, the company announced that the OPERA-02 trial for palazestrant and ribociclib in breast cancer is on track for initiation in 2025. The OPERA-01 monotherapy trial also continues, with results expected in 2026. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has further promising results in clinical data for OP-3136 in multiple cancer types.

Additionally, the company’s trials on VERITAC-2 showed that the drug is more effective for metastatic breast cancer with ESR1 mutations, as it improves survival with a good safety profile. Following these developments, H.C. Wainwright reiterated the Buy rating on the stock while maintaining the price target of $28.00.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is showing a potential short-term rebound, gaining 7.19% this week despite a decline of 67.38% over the past year, attracting the interest of short-term investors.

READ NEXT: 10 Stocks with Huge Catalysts on the Horizon and 11 Best Long Term Low Risk Stocks to Invest in

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.